Humana (HUM) Current Deferred Revenue (2009 - 2026)

Humana (HUM) has reported Current Deferred Revenue for 18 consecutive years, with $249.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Deferred Revenue fell 9.12% year-over-year to $249.0 million in Q2 2026; TTM through Jun 2026 was $249.0 million, a 9.12% decrease from a year earlier, with the FY2025 full-year figure at $356.0 million, up 36.92% from the prior year.
• Current Deferred Revenue was $249.0 million for Q2 2026 at Humana, down from $269.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $7.5 billion in Q3 2023 and troughed at $195.0 million in Q3 2024.
• A 5-year average of $1.8 billion and a median of $280.0 million in 2022 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue jumped 2694.7% in 2023 and sank 97.41% in 2024, its largest moves.
• Over 5 years, Current Deferred Revenue stood at $286.0 million in 2022, then dropped by 6.99% to $266.0 million in 2023, then fell by 2.26% to $260.0 million in 2024, then surged by 36.92% to $356.0 million in 2025, then tumbled by 30.06% to $249.0 million in 2026.
• The last three Current Deferred Revenue figures came in at $249.0 million (Q2 2026), $269.0 million (Q1 2026), and $356.0 million (Q4 2025), per Business Quant data.